Abstract
Tumor necrosis factor (TNF)-α is implicated in the same time in apoptosis and in cell proliferation. TNF-α not only acts as pro-inflammatory cytokine conducing to wide spectrum of human diseases including inflammatory diseases, but can also induce tumor development. The molecular mechanisms of TNF-α functions have been intensively investigated. In this review we covered TNF-α, the molecule, its signaling pathway, and its therapeutic functions. We provide a particular insight in its paradoxical role in tumor promotion and in its use as anti-tumor agent. This review considers also the recent findings regarding TNF-α inhibitors, their pharmacokinetics, and their pharmacodynamics. Six TNF-α inhibitors have been considered here: Infliximab, Adalimumab, Golimumab, CDP870, CDP571, Etanercept, and Thalidomide. We discussed the clinical relevance of their functions in treatment of several diseases such as advanced inflammatory rheumatic and bowel disease, with a focus in cancer treatment. Targeting TNF-α by these drugs has many side effects like malignancies development, and the long-term sequels are not very well explored. Their efficacy and their safety were discussed, underscoring the necessity of close patients monitoring and of their caution use.
Similar content being viewed by others
References
Carswell E, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666–70. doi:10.1073/pnas.72.9.3666.
Feldmann M, et al. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? Novartis Found Symp. 2004;256:53–69. doi:10.1002/0470856734.ch5.
Locksley R, Killeen N, Lenardo M. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487–501. doi:10.1016/S0092-8674(01)00237-9.
Black RA, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729–33. doi:10.1038/385729a0.
Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5:392–9. doi:10.1016/S0962-8924(00)89088-1.
Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717–25. doi:10.1056/NEJM199606273342607.
Aggarwal B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745–56. doi:10.1038/nri1184.
Tartaglia L, Goeddel D. Two TNF receptors. Immunol Today. 1992;13:151–3. doi:10.1016/0167-5699(92)90116-O.
Varfolomeev EE, Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie? Cell. 2004;116:491–7. doi:10.1016/S0092-8674(04)00166-7.
Wertz IE, Dixit VM. Ubiquitin-mediated regulation of TNFR1 signaling. Cytokine Growth Factor Rev. 2008;19:313–24. doi:10.1016/j.cytogfr.2008.04.014.
Chen G, Goeddel D. TNF-R1 signaling: a beautiful pathway. Science. 2002;296:1634–5. doi:10.1126/science.1071924.
Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol. 2005;7:758–65. doi:10.1038/ncb0805-758.
Basak S, Hoffmann A. Crosstalk via the NF-kappa B signaling system. Cytokine Growth Factor Rev. 2008;19:187–97. doi:10.1016/j.cytogfr.2008.04.005.
Brenner DA, O’Hara M, Angel P, Chojkier M, Karin M. Prolonged activation of JUN and collagenase genes by tumour necrosis factor-alpha. Nature. 1989;337:661–3. doi:10.1038/337661a0.
Muppidi JR, Tschopp J, Siegl RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity. 2004;21:461–5. doi:10.1016/j.immuni.2004.10.001.
Kruyt FAE. TRAIL and cancer therapy. Cancer Lett. 2008;263:14–25. doi:10.1016/j.canlet.2008.02.003.
Anderson G, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004;4:314–20. doi:10.1016/j.coph.2004.04.004.
Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003;14:185–91. doi:10.1016/S1359-6101(03)00022-4.
Kruglov A, et al. Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Cytokine Growth Factor Rev. 2008;19:231–44. doi:10.1016/j.cytogfr.2008.04.010.
Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure–function relationship(s). Microsc Res Tech. 2000;50:184–95. doi:10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H.
Stübgen J-P. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37:281–92. doi:10.1002/mus.20924.
Cope AP, et al. Chronic tumor necrosis factor alter T cells responses by attenuating T cell receptor signalling. J Exp Med. 1997;185:1573–84. doi:10.1084/jem.185.9.1573.
Kodama S, Davis M, Faustman D. The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis. Cell Mol Life Sci. 2005;62:1850–62. doi:10.1007/s00018-005-5022-6.
Ban L, et al. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc Natl Acad Sci USA. 2008;105:13644–9. doi:10.1073/pnas.0803429105.
Manusama E, et al. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg. 1996;83:551–5. doi:10.1002/bjs.1800830438.
Eggermont A, de Wilt J, ten Hagen T. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003;4:429–37. doi:10.1016/S1470-2045(03)01141-0.
Curnis F, Sacchi A, Corti A. Improving the response of tumors to chemotherapy in mice by targeted delivery of picogram doses of tumor necrosis factor-alpha to tumor vessels. J Clin Invest. 2002;110:475–82.
Folli S, et al. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer. 1993;53:829–36. doi:10.1002/ijc.2910530521.
van Horssen R, Ten Hagen T, Eggermont A. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11:397–408. doi:10.1634/theoncologist.11-4-397.
ten Hagen T, Seynhaeve A, Eggermont A. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. Immunol Rev. 2008;222:299–315. doi:10.1111/j.1600-065X.2008.00619.x.
Fraker DL, Alexander H, Andrich M, Rosenberg S. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol. 1996;14:479–89.
Van Horssen R, Ten Hagen TLM, Eggermont AMM. TNF-alpha in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility. The Oncologist. 2006;11:397–408. doi:10.1634/theoncologist.11-4-397.
Lejeune F, Rüegg C. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment. Bull Cancer. 2006;93:E90–100.
Fajardo L, Kwan H, Kowalski J, Prionas S, Allison A. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol. 1992;140:539–44.
Alexander HJ, et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16:1479–89.
Borsi L, et al. Selective targeted delivery of TNF alpha to tumor blood vessels. Blood. 2003;102:4384–92. doi:10.1182/blood-2003-04-1039.
Corti A, Ponzoni M. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann NY Acad Sci. 2004;1028:104–12. doi:10.1196/annals.1322.011.
Senzer N, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004;22:592–601. doi:10.1200/JCO.2004.01.227.
Chang K, et al. Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer. Nat Clin Pract Gastroenterol Hepatol. 2008;5:107–11. doi:10.1038/ncpgasthep1033.
Mundt AJ, et al. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res. 2004;10:5747–53. doi:10.1158/1078-0432.CCR-04-0296.
Chung T, et al. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. 1998;5:344–9.
Staba M, Mauceru H, Kufe D, Hallahan D, Weichselbaum R. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 1998;5:293–300. doi:10.1038/sj.gt.3300594.
McLoughlin JM, et al. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor a, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol. 2005;12:825–30. doi:10.1245/ASO.2005.03.023.
Asher AL, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol. 1991;146:3227–34.
Han SK, Brody SL, Crystal RG. Suppression of in vivo tumorigenicity of human lung cancer cells by retrovirus-mediated transfer of the human tumor necrosis factor-alpha cDNA. Am J Respir Cell Mol Biol. 1994;11:270–8.
Mizuguchi H, et al. Tumor necrosis factor alpha-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors. Cancer Res. 1998;58:5727–30.
Larmonier N, et al. The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. Exp Cell Res. 2007;313:2345–55. doi:10.1016/j.yexcr.2007.03.027.
Tselepsis C, et al. Tumour necrosis factor-alpha in Barrett’s oesophagus: a potential novel mechanism of action. Oncogene. 2002;21:6071–81. doi:10.1038/sj.onc.1205731.
Darai E, Detchev R, Hugol D, Quang NT. Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor alpha in women with endometriomas and benign and malignant cycstic ovarian tumours. Hum Reprod. 2003;18:1681–5. doi:10.1093/humrep/deg321.
Szlosarek PW, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer. 2006;42:745–50. doi:10.1016/j.ejca.2006.01.012.
Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002;13:135–41. doi:10.1016/S1359-6101(01)00020-X.
Shealy DJ, Visvanathan S. Anti-TNF antibodies: lessons from the past, roadmap for the future. In: Chernajovsky Y, Nissim A, editors. Therapeutic antibodies. Handbook of experimental pharmacology. 2008, p. 101–129.
Huerta-Yepez SM, Vega M, Garban H, Bonavida B. Involvement of the TNF-alpha autocrine-paracrine loop via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clin Immunol. 2006;120:297–309. doi:10.1016/j.clim.2006.03.015.
Mocellin S, Riccardo Rossi C, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005;16:35–53. doi:10.1016/j.cytogfr.2004.11.001.
Hagemann T, et al. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis. 2004;25:1543–9. doi:10.1093/carcin/bgh146.
Lee HY, et al. A small compound that inhibits tumor necrosis factor-alpha-induced matrix metalloproteinase-9 upregulation. Biochem Biophys Res Commun. 2005;336:716–22. doi:10.1016/j.bbrc.2005.08.154.
Overall CM, Kleifeld O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006;6:227–39. doi:10.1038/nrc1821.
Nagai S, et al. Glil contributs to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation. Cancer Sci. 2008;99:1377–84. doi:10.1111/j.1349-7006.2008.00822.x.
Leber TM, Balkwill FR. Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer. 1998;78:724–32.
Szlosarek PW, Balkwill FR. Tumour necrosis factor: a potential target for the therapy of solid tumours. Lancet Oncol. 2003;4:565–73. doi:10.1016/S1470-2045(03)01196-3.
Zidi I, et al. Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers. Cell Mol Life Sci. 2006;63:2669–81. doi:10.1007/s00018-006-6341-y.
Jang W, et al. The −238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett. 2001;166:41–6. doi:10.1016/S0304-3835(01)00438-4.
Hajeer A, et al. Preliminary evidence of an association of tumour necrosis factor microsatellites with increased risk of multiple basal cell carcinomas. Br J Dermatol. 2000;142:441–5. doi:10.1046/j.1365-2133.2000.03353.x.
Marsh H, et al. Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br J Cancer. 2003;89:1096–101. doi:10.1038/sj.bjc.6601165.
Scallon BJ, Arevalo Moore M, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251–9. doi:10.1006/cyto.1995.0029.
Mitoma H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor-alpha expressing cells comparison among Infliximab, Etanercept, and Adalimumab. Arthritis Rheum. 2008;58:1248–57. doi:10.1002/art.23447.
Daniel PT, Pezzuto A, Dörken B. Humoral immunotherapy and the use of monoclonal antibodies. In: Degos L, LDC, Löwenberg B, editors. Textbook of malignant haematology. Martin Dunitz; 1999, p. 425–46.
Tracey D, Klareskog L, Sasso EH, Salfled Jg, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–79. doi:10.1016/j.pharmthera.2007.10.001.
Duclos M, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol. 2006;33:2433–8.
Schrumpf Heiberg M, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59:234–40. doi:10.1002/art.23333.
Alonso-Ruiz A, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;9:52. doi:10.1186/1471-2474-9-52.
Carmona L, Gomez-Reino JJS, Group B. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis: data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006;8:R72. doi:10.1186/ar1941.
Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with Etanercept and Infliximab in rheumatoid arthritis: results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8:R174. doi:10.1186/ar2084.
Farrell R, et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol. 2000;95:3490–7. doi:10.1111/j.1572-0241.2000.03366.x.
St Clair E, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–43. doi:10.1002/art.20568.
Elliott MJ, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36:1681–90. doi:10.1002/art.1780361206.
Wagner C, et al. lnfliximab treatment benefits correlate with pbarmacodynamic parameters in Crohn’s disease patients. Digestion. 1998;59:124–5.
Nakada M, et al. Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells. Cell Adhes Commun. 1998;5:491–503. doi:10.3109/15419069809005606.
Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119–33.
Hommes D, et al. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn’s disease. Haemostasis. 1997;27:269–77.
Van Dullemen H, et al. Reduction of circulating secretory phospholipase A, levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn’s disease. Relation between tumor necrosis factor and secretory phospholipase A, in healthy humans and active Crohn’s disease. Scand J Gastroenterol. 1998;33:1094–8. doi:10.1080/003655298750026813.
Flamant M, Bourreille A. Biothérapies et MICI: anti-TNF et nouvelles cibles thérapeutiques Biologic therapies in inflammatory bowel disease. Rev Med Interne. 2007;28:852–61. doi:10.1016/j.revmed.2007.06.008.
Baert F, et al. Influence of immunogenicity on the long-term efficacy of Infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–8. doi:10.1056/NEJMoa020888.
Weinblatt M, et al. Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35–45. doi:10.1002/art.10697.
Van der Heijde D, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double blind, placebocontrolled trial. Arthritis Rheum. 2006;54:2136–46. doi:10.1002/art.21913.
Mease P, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–89. doi:10.1002/art.21306.
Keystone E, Haraoui B. Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin North Am. 2004;30:349–64. doi:10.1016/j.rdc.2004.02.004.
Martin PL, Oneda S, Treacy G. Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the Macaque immune system. Am J Reprod Immunol. 2007;58:138–49. doi:10.1111/j.1600-0897.2007.00499.x.
Kay J, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:964–75. doi:10.1002/art.23383.
Zhou H, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47:383–96. doi:10.1177/0091270006298188.
Inman RD, et al. Efficacy and safety of Golimumab in patients with ankylosing spondylitis results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402–12. doi:10.1002/art.23969.
Hutas G. Golimumab, a fully human monoclonal antibody against TNF-alpha. Curr Opin Mol Ther. 2008;10:393–406.
Sandborn WJ, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357:228–38. doi:10.1056/NEJMoa067594.
Schreiber S, et al. Maintenance therapy with Certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–50. doi:10.1056/NEJMoa062897.
Winter G, Harris W. Humanized antibodies. Immunol Today. 1993;14:243–6. doi:10.1016/0167-5699(93)90039-N.
Stack WA, et al. Randomised controlled trial of CDP571 antibody to tumor necrosis factor in Crohn’s disease. Lancet. 1997;349:521–4. doi:10.1016/S0140-6736(97)80083-9.
Sandborn WJ, et al. An open-label study of the human anti-TNF monoclonal antibody Adalimumab in subjects with prior loss of response or intolerance to Infliximab for Crohn’s disease. Am J Gastroenterol. 2004;99:1984–9. doi:10.1111/j.1572-0241.2004.40462.x.
Feagan BG, et al. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;23:617–28. doi:10.1111/j.1365-2036.2006.02791.x.
Sandborn W, et al. Etanercept for active Crohn’s disease: a randomized, double blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–94. doi:10.1053/gast.2001.28674.
Nanda S, Bathon J. Etanercept: a clinical review of current and emerging indications. Expert Opin Pharmacother. 2004;5:1175–86. doi:10.1517/14656566.5.5.1175.
Speirs A. Thalidomide and congenital abnormalities. Lancet. 1962;1:303–5. doi:10.1016/S0140-6736(62)91248-5.
Kumar S, Witzig TE, Rajkumar SV. Thalidomide as an anti-cancer agent. J Cell Mol Med. 2002;6:160–74. doi:10.1111/j.1582-4934.2002.tb00184.x.
Combe B. Le thalidomide: vers de nouvelles indications ? Rev Rhum. 2001;68:951–7. doi:10.1016/S1169-8330(01)00208-3.
Moreira AL, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675–80. doi:10.1084/jem.177.6.1675.
Niwayama S, Turk BE, Liu JO. Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides. J Med Chem. 1996;39:3044–5. doi:10.1021/jm960284r.
Corral LG, et al. Differential cytokine modulation and T cell activation by two distinct classes of Thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380–6.
D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082–5. doi:10.1073/pnas.91.9.4082.
Keifer JA, Guttridge DC, Ashburner BP, Baldwin ASJ. Inhibition of NF-kappa B activity by thalidomide through suppression of Ikappa B kinase activity. J Biol Chem. 2001;276:22382–7. doi:10.1074/jbc.M100938200.
Teo Steven K. Properties of Thalidomide and its analogues: implications for anticancer therapy. AAPS J. 2005;7:E14–9. doi:10.1208/aapsj070103.
Haslett P, Corral L, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885–92. doi:10.1084/jem.187.11.1885.
Laber DA, et al. A phase I study of Thalidomide, Capecitabine and Temozolomide in advanced cancer. Cancer Biol Ther. 2007;6:840–5.
Joshua DE. Multiple myeloma: the present and the future. Med J Aust. 2005;183:344.
Alessandri C, et al. Autoantibody production in anti-TNF-alpha-treated patients. Ann NY Acad Sci. 2007;1110:319–29. doi:10.1196/annals.1423.034.
Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8:601–11. doi:10.1016/S1473-3099(08)70227-5.
Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust. 2005;183:205–8.
Ozorio G, et al. Autoimmune hepatitis following Infliximab therapy for ankylosing spondylitis. Med J Aust. 2007;187:524–6.
Yazisiz V, Avci AB, Erbasan F, Yildirim B, Terzioglu E. Development of Crohn’s disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis. 2008;10:953–4.
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of Infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133–40. doi:10.1161/01.CIR.0000077913.60364.D2.
Keystone EC. Advances in targeted therapy: safety of biological agents. Ann Rheum Dis. 2003;62:ii34–6. doi:10.1136/ard.62.suppl_2.ii34.
Askling J, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1414–20. doi:10.1136/ard.2004.033241.
Bongartz T, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies : systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85. doi:10.1001/jama.295.19.2275.
Okada S, Siegel J. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA. 2006;296:2201–2. doi:10.1001/jama.296.18.2201-b.
Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with Infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265–7. doi:10.1097/MPG.0b013e31802f6424.
Zeidan A, Sham R, Shapiro J, Baratta A, Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn’s disease who received infliximab therapy. Leuk Lymphoma. 2007;48:1410–3. doi:10.1080/10428190701345433.
Drini M, Prichard PJ, Brown GJ, Macrae FA. Hepatosplenic T-cell lymphoma following Infliximab therapy for Crohn’s disease. Med J Aust. 2008;189:464–5.
Geborek P, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699–703. doi:10.1136/ard.2004.030528.
Nair B, Raval G, Mehta P. TNF-alpha inhibitor Etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol. 2007;82:1022–4. doi:10.1002/ajh.20926.
Bakland G, Nossent H. Acute myelogenous leukaemia following Etanercept therapy. Rheumatology. 2003;42:900–1. doi:10.1093/rheumatology/keg128.
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MMT. Tumor necrosis factor antagonist therapy and lymphoma development twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46:3151–8. doi:10.1002/art.10679.
Stone JH, et al. Solid malignancies among patients in the Wegener’s Granulomatosis Etanercept trial. Arthritis Rheum. 2006;54:1608–18. doi:10.1002/art.21869.
Humira™ (Adalimumab), DN0735V7 CR22-05126. December 20, 2002:16p.
Solomon DH. The comparative safety and effectiveness of TNF-alpha antagonists. J Manag Care Pharm. 2007;13:S7–18.
Curnis F, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000;18:1185–90. doi:10.1038/81183.
Kianmanesh A, et al. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naïve dendritic cells elicits significant suppression of tumor growth without toxicity. Hum Gene Ther. 2001;12:2035–49. doi:10.1089/10430340152677395.
Manusama ER, et al. Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam Preclinical-Clinical Program. Semin Surg Oncol. 1998;14:232–7. doi:10.1002/(SICI)1098-2388(199804/05)14:3<232::AID-SSU7>3.0.CO;2-9.
Lewis JD. Anti-TNF antibodies for Crohn’s disease- In pursuit of the perfect clinical trial. N Engl J Med. 2007;357:296–8. doi:10.1056/NEJMe078111.
Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: Rituximab, Omalizumab, Infliximab, Etanercept, Adalimumab, Efalizumab, and Alefacept (Part 2 of 2). J Am Acad Dermatol. 2007;56:e55–79. doi:10.1016/j.jaad.2006.07.019.
Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor blocking agents Adalimumab, Etanercept, and Infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2003;62(Suppl II):ii13–6. doi:10.1136/ard.62.suppl_2.ii13.
Doan QV, Chiou C-F, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (Adalimumab, Etanercept, and Infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12:555–69.
Chen Y-F, et al. A systematic review of the effectiveness of Adalimumab, Etanercept and Infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii–iv, xi–xiii, 1–229.
Thiéfin G, Morelet A, Heurgué A, Diebold M-D, Eschard J-P. Infliximab-induced hepatitis: absence of cross-toxicity with Etanercept. Joint Bone Spine. 2008;75:737–9. doi:10.1016/j.jbspin.2007.12.009.
Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents: A guide for GPs. Aust Fam Physician. 2007;36:1035–8.
Fonseca JE, et al. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors—March 2008 update. Acta Reumatol Port. 2008;33:77–85.
Theis VS, Rhodes JM. Minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:19–30.
Gupta A, Street AC, Macrae FA. Tumour necrosis factor alpha inhibitors: screening for tuberculosis infection in inflammatory bowel disease. MJA. 2008;188:168–70.
Tayal V, Kalra B. Cytokines and anti-cytokines as therapeutics—an update. Eur J Pharmacol. 2008;579:1–12. doi:10.1016/j.ejphar.2007.10.049.
Schreiber S, et al. A randomized, placebo-controlled trial of Certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129:807–18. doi:10.1053/j.gastro.2005.06.064.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zidi, I., Mestiri, S., Bartegi, A. et al. TNF-α and its inhibitors in cancer. Med Oncol 27, 185–198 (2010). https://doi.org/10.1007/s12032-009-9190-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-009-9190-3